View in browser  | How to whitelist us

NutraIngredients.com
Sponsored By

News & Analysis on Supplements, Health & Nutrition - Europe

11 October 2019

Editor's Spotlight: Science & Regulation

Cannabis group cites uncertainty in refusal to submit Novel Foods application

Cannabis Trades Association (CTA) members will not submit a Novel Foods application for its cannabis containing products as it cites the uncertainty of the regulation’s scope as the main reason. Read more

SPONSORED: SPONSORED LINK

Demystifying collagen and its use in joint health

Join Bioiberica for ‘Demystifying collagen: Understanding its forms and use in joint health’ - a webinar exploring different types of collagen, understanding terminology and knowing the difference in the mechanism of action. Scientific data and evidence of the efficacy of native collagen type II for joint health will also be discussed, referencing Bioiberica’s native type II collagen – b-2cool®.

Click Here

RELATED CONTENT

Gulf in CBD product quality laid bare as calls for tighter controls amplify

A cannabidiol (CBD) manufacturer is calling for greater regulatory controls after independent analyses of 31 CBD-based products found varying levels of active ingredients as well as CBD-related labelling issues. Read more

Slovakia softens regulatory stance on CBD supplement use

Slovakia looks to have eased its stance on cannabidiol (CBD) use as the country’s government deletes it from a list of psychotropic ingredients, essentially classing CBD as a non-regulated substance. Read more

CBD and sports nutrition: Summit to shine light on legal wrangling deciding ingredient’s future

NutraIngredients’ Sports Nutrition Summit provides an opportunity to get the latest regulatory updates of new ingredients such as cannabidiol (CBD) and its potential role in sports nutrition. Read more

divider
William Reed Business Media
© William Reed Business Media Ltd 2019. All rights reserved.
Registered Office: Broadfield Park, Crawley RH11 9RT
Registered in England No. 2883992. VAT No. 644 3073 52.
Unsubscribe Here | Terms & Conditions | Privacy Policy
EMEA